Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeted Therapy in Newly Diagnosed DLBCL With TP53 Mutation
NCT07499271Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of orelabrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Progression-Free Survival at 2 years. Started Jan 2026; status: recruiting.
02
Drugs
orelabrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07499271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07499271.